From March 1, 2026, the immunotherapy drugs nivolumab (Opdivo®) and ipilimumab (Yervoy®) are now listed on the PBS under a world-first pan-tumour (tumour-agnostic) approval.
This means patients with advanced, metastatic, or relapsed rare ovarian cancers (like clear cell, low grade serous, granulosa cell, and other subtypes) can access these treatments based on their oncologist’s judgement and the best clinical evidence.
No more crushing out-of-pocket costs of $100,000+ per course. Eligible patients now pay just $25 per script (or $7.70 concession) – the same as for common cancers!
Prescribing is based on your oncologist’s clinical judgement and the best evidence – a huge step toward equity for those with rarer diagnoses who previously missed out.
Rare Ovarian Cancer Inc (ROC Inc) celebrates this progress toward fairer treatment options. We remain dedicated to funding targeted research (like at Hudson Institute) to uncover better therapies for these under-represented cancers. Keep advocating, keep researching, keep rocing! 💪🩵
Thank you to everyone who’s supporting our mission – your donations and voices help drive change like this.
Thank you to everyone who’s supporting our mission – your donations and voices help drive change like this.